Can China's third-generation IVF screen for genetic diseases? China's third-generation IVF (Preimplantation Genetic Testing, PGT) can screen for chromosomal numerical abnormalities, structural abnormalities (such as translocations, inversions), and some single-gene genetic diseases (such as thalassemia, spinal muscular atrophy, hereditary deafness, etc.), but only if the pathogenic gene is clear and detectable through embryo biopsy. It cannot screen for polygenic genetic diseases (such as hypertension, diabetes), de novo mutations, or mitochondrial diseases. Suitable candidates include carriers of chromosomal abnormalities, those with a family history of known single-gene disorders, those with recurrent miscarriage, or advanced maternal age. The process includes ovarian stimulation, egg retrieval, embryo culture, biopsy, genetic testing, and transfer, taking about 2-3 months in total. Attention should be paid to technical limitations (such as misdiagnosis of mosaicism, no embryos available) and ethical restrictions.
Direct Q&A: The Boundaries of Genetic Disease Screening with Third-Generation IVF
China's third-generation IVF technology (PGT, Preimplantation Genetic Testing) can screen for some genetic diseases, but cannot screen for all genetic diseases. The specific capability depends on the type of genetic disease, whether the pathogenic gene is clear, and whether effective detection methods exist.
- Can screen for: Chromosomal numerical abnormalities (such as Trisomy 21, Trisomy 18), chromosomal structural abnormalities (reciprocal translocation, Robertsonian translocation, inversion), single-gene genetic diseases (autosomal dominant/recessive/X-linked, such as thalassemia, spinal muscular atrophy SMA, hereditary deafness, cystic fibrosis, Huntington's disease, etc.) — requires that the pathogenic gene is clearly mapped and the specific mutation site is identified in the family.
- Cannot screen for: Polygenic genetic diseases (hypertension, type 2 diabetes, schizophrenia, etc., determined by multiple genes + environmental factors), mitochondrial diseases (currently difficult for domestic PGT technology to cover), de novo mutations (spontaneous mutations at the embryonic stage, not carried by parents), imprinting disorders (such as Angelman syndrome, partly caused by epigenetic abnormalities).
- Can screen conditionally: Certain X-linked recessive genetic diseases (gender selection combined with genetic testing), HLA matching (to treat an affected sibling) — requires ethics committee approval.
Why Third-Generation IVF Cannot Screen for All Genetic Diseases
There are three main technical limitations:
- Detection principle limitations: Current mainstream PGT technologies (NGS sequencing or SNP arrays) require removing 5-10 cells from the embryo for amplification analysis. Single-cell amplification can introduce allele dropout (ADO) or amplification bias, reducing detection accuracy for certain complex structures or repetitive sequence regions.
- Genotype-phenotype correlation uncertainty: Many genetic diseases exhibit incomplete penetrance, variable expressivity, or the influence of modifier genes. Even if a pathogenic mutation is found, it is difficult to accurately predict whether the embryo will eventually develop the disease and its severity.
- Ethical and regulatory restrictions: China's "Technical Specifications for Preimplantation Genetic Diagnosis" stipulates that PGD (i.e., PGT-M) is only used for cases with "a clear family history of genetic disease" or "chromosomal abnormalities." It does not allow genetic selection for non-medical purposes, such as intelligence, appearance, or height. Additionally, the scope of testing must be approved by the hospital's ethics committee.
Doctor's Perspective: When consulting, reproductive geneticists will first require the couple to undergo carrier screening or family verification to confirm whether the pathogenic mutation can be detected. If the mutation site cannot be captured by existing probes, or if the patient refuses the risks of embryo biopsy, the doctor will recommend prenatal diagnosis as an alternative. Third-generation IVF is not an insurance policy for genetic diseases but a technological choice for specific scenarios.
Specific Process: How Third-Generation IVF Screens for Genetic Diseases in China
| Step | Content | Duration |
|---|---|---|
| 1. Genetic Counseling | Collect family history, determine inheritance pattern, identify pathogenic gene and mutation site | 1-2 weeks |
| 2. Family Verification | Blood draw from patient and immediate relatives to verify mutation site and ensure detection probe effectiveness | 2-4 weeks |
| 3. Ovarian Stimulation & Egg Retrieval | Controlled ovarian stimulation, ultrasound monitoring, egg retrieval surgery | 12-15 days |
| 4. Embryo Culture | Intracytoplasmic sperm injection (ICSI), culture to blastocyst stage (5-6 days) | 5-6 days |
| 5. Embryo Biopsy | Remove approximately 5 cells from the trophectoderm of the blastocyst under a microscope | 1 day |
| 6. Genetic Testing | Whole genome amplification followed by NGS or array testing to analyze chromosomal copy number and specific gene loci | 2-4 weeks |
| 7. Genetic Counseling & Transfer | Select embryos without the pathogenic gene and with normal chromosomes for frozen-thawed transfer based on test results | 1 menstrual cycle |
From the start of the cycle to transfer, the total duration is about 2-4 months. Actual time depends on ovarian response, number of embryos, and testing cycle.
Easily Overlooked Details: Biopsy and Mosaicism
- Embryo Mosaicism: A blastocyst may contain some cells with normal chromosomes and some with abnormalities. The 5 biopsied cells may not represent the entire embryo. Therefore, PGT reports will indicate "normal/abnormal/mosaic." Mosaic embryos (20%~80% abnormal cells) can be transferred but require prenatal diagnosis confirmation.
- Allele Dropout: During single-cell amplification, only one allele may be amplified, leading to a false normal diagnosis. Therefore, linkage analysis (haplotype analysis) must be used simultaneously to improve accuracy.
- Risk of No Usable Embryos: For carriers of chromosomal translocations, the probability of forming a normal embryo may be only 1/18 or lower. It is necessary to accept the possibility of "cycle cancellation" or "no embryos available for transfer" in advance.
Suitability and Precautions for Different Groups
| Group | Suitable for Third-Generation IVF Genetic Screening? | Special Reminder |
|---|---|---|
| Carriers of Balanced Chromosomal Translocation | Suitable, PGT-SR can screen for normal or carrier-type embryos | Chromosomal microarray (CMA) is also needed to rule out small fragment abnormalities |
| Couples Carrying Single-Gene Disorders (e.g., α/β thalassemia, SMA) | Suitable, PGT-M accuracy >95% | Mutation site must be confirmed in the family first, otherwise probes cannot be designed |
| Advanced Maternal Age (≥38 years) | Partially suitable, can screen for aneuploidy (PGT-A improves implantation rate) | PGT-A does not test for specific gene diseases, only chromosomal numerical abnormalities. Strict age indications apply domestically. |
| Unexplained Recurrent Miscarriage | PGT-A can be attempted, but evidence level is moderate | Maternal factors and uterine abnormalities must be ruled out |
| Couples with Genetic Disease but Unknown Mutation | Not suitable, must wait for pathogenic gene identification | Whole exome sequencing (WES) is recommended to find the cause |
Cost Influencing Factors and Approximate Range
- Basic Costs: Ovarian stimulation + egg retrieval + embryo culture + biopsy + genetic testing + transfer, total cost per cycle is approximately 30,000-50,000 RMB (public hospital) or 50,000-80,000 RMB (private fertility center).
- Additional Costs: Family verification (approximately 10,000-20,000 RMB), embryo freezing (2,000-4,000 RMB per year), multiple transfers (approximately 3,000-5,000 RMB each).
- Insurance Coverage: Most provinces and cities in China have not included it in medical insurance. Some pilot areas in Beijing have included assisted reproductive technology in Class A medical insurance, but PGT is not yet fully covered. Consult the local medical insurance bureau.
Practitioner Observations: Most Common Misconceptions
In real clinical outpatient settings, patients' misconceptions about third-generation IVF screening for genetic diseases center on three points:
- "Third-generation IVF can guarantee a completely healthy child" — Incorrect. PGT can only rule out known specific gene or chromosome problems, but cannot rule out all birth defects, single-gene de novo mutations, or developmental abnormalities. Prenatal diagnosis (amniocentesis) is still routinely recommended.
- "Embryos found to carry a pathogenic gene cannot be used" — Not entirely. For some recessive genetic diseases (e.g., thalassemia carriers), if the embryo is only a carrier (heterozygous) and will not develop the disease, it can be selected for transfer. Phenotype interpretation by a genetic counselor is needed.
- "Anyone with a family history of genetic disease can undergo third-generation IVF" — Wrong. Requirements: 1) Clear inheritance pattern; 2) Pathogenic gene identified; 3) Couple accepts ethical review. For some genetic diseases like polycystic kidney disease, Marfan syndrome, etc., due to high phenotypic variability, some domestic centers may refuse.
Risk Reminder: The probability of damage to the blastocyst from embryo biopsy is about 1%~3%, which may cause delayed embryo development or reduced survival rate. Additionally, the false negative rate (missed diagnosis) for PGT-M testing is about 1%~2%, and the false positive rate (misdiagnosis) is about 0.1%~0.5%. After transfer, prenatal diagnosis (amniocentesis or chorionic villus sampling) is still recommended at 18-22 weeks of pregnancy for verification.
Common Consultation Questions
- Q: Can China's third-generation IVF screen for genetic diseases like hemophilia?
A: Yes, but the pathogenic mutation site in the F8 or F9 gene must first be identified in the family. If the mutation site cannot be confirmed, gender selection (male embryos have a higher probability of the disease) may be used to reduce risk, but gender selection requires ethical approval. - Q: What materials need to be prepared?
A: ID cards of both parties, marriage certificate, birth permit (cancelled in some areas); genetic medical records, genetic test reports, blood samples from family members (parents and affected relatives). All reports must be issued by a tertiary hospital. - Q: Is it better to do it abroad than in China?
A: Abroad (USA, Thailand, Malaysia) may have more comprehensive probe libraries for some rare mutation detections, but the level of top domestic reproductive centers (Peking University Third Hospital, CITIC Xiangya, Shandong University Reproductive Hospital, etc.) is comparable. Note that foreign PGT costs are 2-3 times higher and involve legal, language, and embryo transport risks.
Suggestions for Next Steps
If you are considering using third-generation IVF to screen for genetic diseases, it is recommended to proceed in the following order:
- Make an appointment at a domestic reproductive center with PGT qualifications (check the National Health Commission website for "Medical Institutions Approved to Carry Out Preimplantation Genetic Diagnosis").
- Bring all previous genetic test reports for a genetic counseling outpatient visit. The doctor will assess suitability and order family verification.
- Complete family verification (about 1 month). Once the probe is confirmed effective, proceed to the cycle start.
- Arrange work and rest time in advance, as multiple hospital visits are required during ovarian stimulation.
- Check blood HCG 14 days after transfer. If pregnancy is successful, be sure to undergo prenatal diagnosis to verify the results.
Comments (0)